Go to the list of all blogs
Rick Pendergraft's Avatar
published in Blogs
Sep 19, 2019

Astrazeneca hits lower rail of an upward sloped trend channel

Pharmaceutical manufacturer Astrazeneca (NYSE: AZN) has been trending higher over the last three and a half months and a trend channel has formed that defines the various cycles within the overall trend. The stock bounced off of the lower rail of that channel earlier this week and now the stock looks poised to move higher in the coming weeks.

The 5o-day moving average is just above the lower rail and that gives the stock two layers of support to help it. We also see on the chart that the daily stochastic readings were flirting with oversold territory before making a bullish crossover on September 18. Similar developments in July and May were really good buy signals for the stock.

In addition to the oversold readings from the 10-day RSI and the stochastic readings, the stock dropped below its lower Bollinger Band on September 10. A price increase is expected as the stock heads toward the middle band. In 20 of 38 cases where Astrazeneca's price broke its lower Bollinger Band, its price rose further in the following month.

Over the past year, Astrazeneca’s relative strength rating from Investor’s Business Daily is a 74, meaning that the stock is in the top 26% of all companies in IBD’s database from a price appreciation perspective.

Tickeron’s Price Growth Rating for Astrazeneca is 28, indicating outstanding price growth. The stock’s price has increased at a higher rate over the last 12 months as compared to S&P 500 index constituents. A rating of 1 points to highest price growth (largest percent return) while a rating of 100 points to lowest price growth (smallest percent return).

In addition to the technical indicators that are pointing toward an upside move for Astrazeneca, there are a number of fundamental indicators that are really positive for the stock. First, the company boasts a return on equity of 28.5% and a profit margin of 27.4%. Both of these figures are well above average. These two indicators are contributing factors as to why the company gets an SMR rating of 17 from Tickeron. This indicates that the company has very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents.

Also from Tickeron, the Profit vs. Risk Rating for Astrazeneca is 31, indicating low risk on high returns. The average Profit vs. Risk Rating for the industry is 89, placing this stock better than average.

The Tickeron PE Growth Rating for Astrazeneca is 21, pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents. A rating of 1 indicates highest PE growth while a rating of 100 indicates lowest PE growth.

As well as the company and the stock have performed over the past year, the sentiment toward Astrazeneca is anything but overly bullish. According to the Wall Street Journal, there are 24 analysts covering the stock at this time and 16 have it rated as a “buy”. There are five “hold” ratings and three “sell” ratings. This puts the buy percentage at 66.7%. This is in the lower portion of the average range. The average buy percentage is in the 65% to 75% range.

The short interest ratio is higher than average at 5.4 and that is surprising for a company like Astrazeneca. The number of shares sold short increased from 15.47 million shares to 16.32 million during the second half of August and that suggest the bearish sentiment is growing.

Related Ticker: AZN

AZN in upward trend: 10-day moving average moved above 50-day moving average on March 08, 2024

The 10-day moving average for AZN crossed bullishly above the 50-day moving average on March 08, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where AZN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on March 27, 2024. You may want to consider a long position or call options on AZN as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AZN just turned positive on March 27, 2024. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

AZN moved above its 50-day moving average on March 07, 2024 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in of 336 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 261 cases where AZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AZN moved out of overbought territory on March 12, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AZN broke above its upper Bollinger Band on March 27, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.405) is normal, around the industry mean (5.792). P/E Ratio (35.824) is within average values for comparable stocks, (49.793). Projected Growth (PEG Ratio) (0.883) is also within normal values, averaging (3.057). Dividend Yield (0.021) settles around the average of (0.029) among similar stocks. P/S Ratio (4.653) is also within normal values, averaging (3.723).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AZN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 87.5B. The market cap for tickers in the group ranges from 72.83K to 739.87B. LLY holds the highest valuation in this group at 739.87B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -2%. SCLX experienced the highest price growth at 18%, while MIRA experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was 4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 29
P/E Growth Rating: 61
Price Growth Rating: 50
SMR Rating: 58
Profit Risk Rating: 70
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
AZNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1 Francis Crick Avenue
Phone
+44 2037495000
Employees
89900
Web
https://www.astrazeneca.com
Ad is loading...
Discover the dynamic world of cryptocurrency trading with Tickeron's AI analysis. Capitalize on bullish and bearish patterns in Origin Protocol (OGN.X), with gains up to 27.80%. Stay ahead with Tickeron's real-time insights and make informed trading decisions. #CryptoTrading #AIAnalysis #OriginProtocol #InvestSmart
#latest#popular#patterns#artificial_intelligence#trading#technical_analysis
Dive into the world of trading excellence with our Best AI Robot of the week! In a market characterized by growth, the key to maximizing profits lies not only in mainstream large-cap stocks but also in exploring opportunities across different market segments.
This article delves into the performance of AI trading robots, specifically those utilizing the "Swing trader: Long-Short Equity Strategy (TA&FA)." These bots showcased their prowess by delivering a notable +4.98% gain while engaging in MRNA trades over the previous week. Beyond mere statistics, we explore the technical indicators and recent earnings report of MRNA to shed light on the underlying dynamics influencing the stock.
Artificial intelligence (AI) trading bots have become powerful tools for investors seeking active trading opportunities. In a recent analysis conducted on the "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" platform, AI trading bots exhibited impressive performance, generating a noteworthy +4.81% gain while actively trading Shopify (SHOP) over the course of the previous week.
In the dynamic world of finance, strategic asset acquisition is a game-changer. Recently, a group of stocks within this domain has been in the spotlight, showcasing notable performances and intriguing patterns. This article delves into the recent movements of these stocks, focusing on key indicators, market capitalization, notable price events, and volume dynamics.
Urology companies, comprising EDAP (EDAP), Teleflex (TFX), and UroGen Pharma (URGN), have shown a remarkable +6.67% increase in performance over the last week. In this analysis, we delve into various indicators and metrics to better understand the current landscape and individual trajectories within this thematic sector.
In the ever-evolving landscape of financial markets, Artificial Intelligence (AI) trading robots have emerged as potent tools for investors seeking an edge. The recent performance of the AI trading robots accessible through "Swing Trader, Popular Stocks: Short Bias Strategy (TA&FA)" has caught the attention of market participants. Notably, these bots generated an impressive +10.22% gain in a week, with a focus on trading TSM (Taiwan Semiconductor Manufacturing Company).
In the fast-paced world of stock trading, artificial intelligence (AI) has become a game-changer, with trading robots demonstrating impressive results. The "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)" platform recently showcased the effectiveness of its bots, generating a notable +7.86% gain while actively trading AMD over the past week.
​​​​​​​Aluminum companies have witnessed a remarkable surge in performance, with a collective increase of +8.75% over the past week. In this analysis, we delve into the dynamics of this surge, focusing on key indicators and individual stock movements. The tickers in focus are CENX, AA, KALU, and CSTM.
​​​​​​​Propane gas companies, represented by tickers NGL, SGU, and SPH, have exhibited a remarkable +8.22% increase in performance over the past week. This surge is substantiated by various technical indicators, fostering a positive outlook for investors. In this analysis, we delve into key indicators, market capitalization, notable price movements, and volume fluctuations to provide a comprehensive understanding of the current landscape.
The Tickeron quant team is delighted to introduce our best robot of the week tailored for Trend Traders. Our sophisticated AI Robot, has been designed for manual trading enthusiasts who value independent signal selection.
In the fast-paced world of AI trading, algorithms powered by sophisticated technical analysis tools are making waves. The "Swing trader: Top High-Volatility Stocks v.2 (TA)" bots have proven their mettle, securing a remarkable +6.02% gain in a week of trading AVGO.
Artificial intelligence (AI) trading robots have become an integral part of the market landscape. One such example is the "Swing Trader, Popular Stocks: Short Bias Strategy (TA&FA)" bot, which showcased impressive results with a +5.54% gain while trading LRCX over the past week. In this article, we delve into the technical analysis of LRCX, examining its recent earnings report and broader industry trends.
The drilling industry has recently experienced a commendable upswing, with a substantial 8.22% surge in performance over the past week. In this article, we will dissect the current dynamics of key players in this sector, focusing on prominent tickers such as DO, RIG, HP, NBR, NR, PDS, and PTEN.
In the realm of AI-driven trading, the "Swing Trader: ETFs for Growing Industries (TA)" platform recently showcased impressive results, with its trading bots generating a noteworthy +5.09% gain while actively trading TQQQ over the past week. As we delve into the intricacies of these AI trading strategies, let's dissect the recent earning results and market indicators to better understand the driving forces behind their success.
In the fast-paced world of AI-driven trading, the utilization of sophisticated algorithms and technical analysis tools is becoming increasingly prevalent. One notable example is the Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA), which demonstrated its prowess by generating a commendable +5.02% gain while trading NVDA over the past week. Let's delve into the technical indicators and earnings results to gain a comprehensive understanding of NVDA's current market standing.
In the fast-paced realm of biotech and pharmaceuticals, a group of stocks, including giants like Johnson & Johnson (JNJ), Amgen (AMGN), Pfizer (PFE), Astex Pharmaceuticals (ATXS), AnaptysBio (ANAB), and Zymeworks (ZYME), witnessed a noteworthy 8.55% surge in performance over the past week. However, a closer look at various indicators suggests caution, signaling a potential downturn.
In the dynamic landscape of the energy sector, onshore oil exploration companies have recently experienced a remarkable upswing, with a notable 7.13% increase in performance over the past week. This surge has captivated market attention, and several key indicators point towards a sustained positive outlook. In this analysis, we delve into the financial health, market dynamics, and recent events surrounding prominent tickers in this domain - PXD, CNQ, PDS, PTEN, and FANG.
Tickeron's Quant team is delighted to introduce our latest AI-powered robot designed for trading small-cap stocks, employing a distinctive fundamental stock analysis algorithm. This algorithm, renowned for its blend of in-depth analysis and intuitive signal-following capabilities, is well-suited for both novice and seasoned traders.
In the dynamic world of stock trading, the utilization of AI trading robots has become increasingly prevalent. One such example is the "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," which showcased its prowess by yielding a remarkable +4.98% gain while trading ZIM over the previous week. As we delve into the intricacies of ZIM's recent performance, let's analyze the earnings results, market indicators, and industry trends that shape the narrative.